http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 18 Jun 2026 16:02:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html si-local-file:///var/storage/secattach/20260618/26665825.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html Thu, 18 Jun 2026 16:02:00 -0400 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html si-local-file:///var/storage/secattach/20260618/26665825.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+17/26665825.html Thu, 18 Jun 2026 16:02:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Caribou+Biosciences+Inc.+%28CRBU%29/26650138.html <p>H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $11.00 price target on Caribou Biosciences Inc. (NASDAQ: CRBU).</p><p>The analyst commented: "At EHA, Caribou presented updated data from the ANTLER trial, which is evaluating vispa-cel (CB-010) in 2L+ CD19-targeted therapy-naive LBCL patients. As seen in the presentation, a single dose of 80×106 optimized vispa-cel CAR-T cells—defined as cells from a donor <30 years old with >2 matched HLA alleles between patient and donor—achieved an 82% ORR (67% CR) and a 17.1-month mPFS in 27 2L LBCL patients. These results are noteworthy for two key reasons. First, vispa-cel’s 17.1-month mPFS exceeds http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Caribou+Biosciences+Inc.+%28CRBU%29/26650138.html Tue, 16 Jun 2026 06:48:37 -0400 CRBU http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Press+Releases/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html <p align="left"><em>Issued on behalf of GT Biopharma, Inc.</em></p> <p align="left"><em>Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else.</em></p> <p align="left">SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=hqf29VbrX-9-C6m0V_cBNDnlGi6-4EsKJBh9s-pfYkgKAaNL-Sl-aDcqy-saXEknyLtkiiZlV89PSyldUHVuRMeUUNE3qN9JlScOHrJUg7w=" rel="nofollow" target="_blank">Equity Insider</a> News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. http://www.streetinsider.com/Globe+Newswire/After+CAR-T%2C+the+Next+Frontier+in+Cancer+Immunotherapy+May+Belong+to+a+Different+Immune+Cell/26638457.html Fri, 12 Jun 2026 08:10:00 -0400 CMPX CRBU FATE GTBP NKTX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+11/26632916.html si-local-file:///var/storage/secattach/20260611/26632916.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+11/26632916.html Thu, 11 Jun 2026 08:03:00 -0400 CRBU O.51128759 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+11/26632916.html si-local-file:///var/storage/secattach/20260611/26632916.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Caribou+Biosciences%2C++++++For%3A+Jun+11/26632916.html Thu, 11 Jun 2026 08:03:00 -0400 CRBU O.51128759 http://www.streetinsider.com/Corporate+News/Caribou+reports+long-term+data+for+vispa-cel+in+lymphoma+patients/26632902.html <p>Caribou Biosciences Inc. (NASDAQ: CRBU) announced long-term efficacy data for its experimental cell therapy vispa-cel in patients with second-line large B cell lymphoma. The data was presented at the European Hematology Association Annual Meeting on June 12, 2026.</p><p>In the ANTLER phase 1 clinical trial, 27 second-line large B cell lymphoma patients received a single dose of 80 million vispa-cel CAR-T cells. The treatment achieved an 82% overall response rate and a 67% complete response rate, with a median progression-free survival of 17.1 months as of the March 6, 2026 data cutoff.</p><p>The safety profile showed no reports of graft-versus-host disease or http://www.streetinsider.com/Corporate+News/Caribou+reports+long-term+data+for+vispa-cel+in+lymphoma+patients/26632902.html Thu, 11 Jun 2026 08:02:19 -0400 CRBU http://www.streetinsider.com/FDA/Caribou+reports+long-term+data+for+vispa-cel+in+lymphoma+patients/26632902.html <p>Caribou Biosciences Inc. (NASDAQ: CRBU) announced long-term efficacy data for its experimental cell therapy vispa-cel in patients with second-line large B cell lymphoma. The data was presented at the European Hematology Association Annual Meeting on June 12, 2026.</p><p>In the ANTLER phase 1 clinical trial, 27 second-line large B cell lymphoma patients received a single dose of 80 million vispa-cel CAR-T cells. The treatment achieved an 82% overall response rate and a 67% complete response rate, with a median progression-free survival of 17.1 months as of the March 6, 2026 data cutoff.</p><p>The safety profile showed no reports of graft-versus-host disease or http://www.streetinsider.com/FDA/Caribou+reports+long-term+data+for+vispa-cel+in+lymphoma+patients/26632902.html Thu, 11 Jun 2026 08:02:19 -0400 CRBU http://www.streetinsider.com/Corporate+News/Caribou+Biosciences+reports+durable+responses+for+CB-011+therapy/26632871.html <p>Caribou Biosciences Inc. (NASDAQ: CRBU) reported extended follow-up data for its CB-011 therapy in treating relapsed or refractory multiple myeloma patients. The data was presented at the 2026 European Hematology Association Annual Meeting.</p><p>In the dose escalation portion of the CaMMouflage phase 1 trial, 12 BCMA-naïve patients received the recommended dose of 450 million CB-011 CAR-T cells. With a median follow-up of 17.7 months, the treatment showed a 92% overall response rate and an 83% complete response rate. Additionally, 91% of evaluable patients achieved minimal residual disease negativity, and 50% of patients maintained complete response at 15 months.</p><p>The company also reported http://www.streetinsider.com/Corporate+News/Caribou+Biosciences+reports+durable+responses+for+CB-011+therapy/26632871.html Thu, 11 Jun 2026 08:01:35 -0400 CRBU http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html <p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p> <p align="center"><em>-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --</em></p> <p align="center"><em>-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --</em></p> <p align="center"><em>-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --</em></p> <p>BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html Thu, 11 Jun 2026 08:01:00 -0400 A.03607790 A.21759080 CRBU O.00392134 O.20147506 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html <p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p> <p align="center"><em>-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --</em></p> <p align="center"><em>-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --</em></p> <p align="center"><em>-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --</em></p> <p>BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html Thu, 11 Jun 2026 08:01:00 -0400 A.03607790 A.21759080 CRBU O.00392134 O.20147506 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html <p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p> <p align="center"><em>-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --</em></p> <p align="center"><em>-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --</em></p> <p align="center"><em>-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --</em></p> <p>BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html Thu, 11 Jun 2026 08:01:00 -0400 A.03607790 A.21759080 CRBU O.00392134 O.20147506 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html <p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p> <p align="center"><em>-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --</em></p> <p align="center"><em>-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --</em></p> <p align="center"><em>-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --</em></p> <p>BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html Thu, 11 Jun 2026 08:01:00 -0400 A.03607790 A.21759080 CRBU O.00392134 O.20147506 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html <p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p> <p align="center"><em>-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --</em></p> <p align="center"><em>-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --</em></p> <p align="center"><em>-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --</em></p> <p>BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html Thu, 11 Jun 2026 08:01:00 -0400 A.03607790 A.21759080 CRBU O.00392134 O.20147506 O.51128759 http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html <p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p> <p align="center"><em>-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --</em></p> <p align="center"><em>-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --</em></p> <p align="center"><em>-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --</em></p> <p>BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Press+Releases/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html Thu, 11 Jun 2026 08:01:00 -0400 A.03607790 A.21759080 CRBU O.00392134 O.20147506 O.51128759 http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html <p align="center"><em>-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS --</em></p> <p align="center"><em>-- Generally well-tolerated safety profile continues to support outpatient administration and further expansion to community centers --</em></p> <p align="center"><em>-- ANTLER-3 pivotal phase 3 trial designed to address the unmet need in 2L LBCL patients at academic and community centers who lack treatment options with curative intent --</em></p> <p align="center"><em>-- EHA oral presentation scheduled for Friday, June 12, 2026, at 5:15pm CEST --</em></p> <p>BERKELEY, Calif., June 11, 2026 (GLOBE NEWSWIRE) -- <a http://www.streetinsider.com/Globe+Newswire/Caribou+Biosciences+Reports+Long-Term+Vispa-cel+Data+in+Second-line+Large+B+Cell+Lymphoma+at+EHA+2026/26632869.html Thu, 11 Jun 2026 08:01:00 -0400 A.03607790 A.21759080 CRBU O.00392134 O.20147506 O.51128759